Invivoscribe, Novartis Partner on Companion Dx for AML | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) –Invivoscribe announced on Tuesday a collaboration with Novartis to develop a companion diagnostic for acute myeloid leukemia patients.

The test will be for the identification of FLT3-positive AML patients for treatment with Novartis' midostaurin, or PKC412, a targeted small molecule inhibitor of FLT3 tyrosine kinase. The drug is currently in Phase III clinical development for newly diagnosed patients with FLT3 mutated AML.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.